Biocon announced that Health Canada has granted a Notice of Compliance (NOC) for Bosaya (denosumab), a biosimilar to Prolia, and Vezuo (denosumab), a biosimilar to Xgeva, on 03 April 2026. Both ...
Biocon receives Health Canada approval for Bosaya and Vevzuo biosimilars, treating osteoporosis and cancer-related bone ...
6h
Health Canada Approves Biocon's Denosumab Biosimilars for Osteoprosis, Cancer-Related Bone Conditons
Global biopharmaceutical company Biocon Limited on Tuesday said Health Canada has granted a Notice of Compliance for its biosimilar Bosaya and Vevzuo, both denosumab-based products used in treating ...
Bengaluru: Biocon Limited has received a Notice of Compliance (NOC) from Health Canada for its denosumab biosimilars Bosaya ...
New Delhi, Apr 21 (PTI) Biocon Ltd on Tuesday said it has received a notice of compliance from Health Canada for its biosimilars Bosaya and Vevzuo, indicated for the treatment of osteoporosis and bone ...
Asianet Newsable on MSN
Biocon gets Health Canada nod for biosimilars Bosaya and Vevzuo
Biocon announced Health Canada's approval for its biosimilars Bosaya and Vevzuo. These denosumab-based products are used to ...
Biocon Receives Health Canada Approval of Bosaya™ and Vevzuo™ (Denosumab biosimilars to Prolia® and Xgeva®) for bone health.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results